
Opinion|Videos|April 11, 2025
Managing Safety and Quality of Life With Cemiplimab in Advanced NSCLC
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how balancing survival benefits with quality of life involves careful monitoring of treatment-related adverse effects. Managing immune-related adverse events in patients on immune checkpoint inhibitors like cemiplimab requires early detection, timely intervention and proactive strategies to minimize impact on outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are potential survival benefits balanced with impacts on patients’ quality of life, particularly in the context of treatment-related adverse effects?
- How do you approach the management of immune-related adverse events in patients receiving immune checkpoint inhibitors like cemiplimab?
- What proactive strategies do you use to minimize the impact of treatment-related adverse events on patient outcomes?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5


























